Trial · NCT07159750
Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
NCT07159750, Recruiting, Hospital Universitari Vall d'Hebron Research Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine. Trials, record NCT07159750. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07159750
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
- NCT number
- NCT07159750
- Status
- Recruiting
- Enrollment
- 700 participants, estimated
- Lead sponsor
- Hospital Universitari Vall d'Hebron Research Institute
- Conditions
- Migraine, Episodic Migraine, Chronic Migraine, Headache
- Interventions
- CGRP antibody or gepant
- First posted
- 2025-09-08
- Last updated
- 2025-09-08
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Monthly Headache Days and Monthly Migraine Days | Through study completion, an average of 2 years | |
| Secondary | HIT-6 | Through study completion, an average of 2 years | Change in HIT-6 (Headache Impact Test) scale, to assess migraine impact. |
| Secondary | MIDAS | Through study completion, an average of 2 years | Change in MIDAS (Migraine Disability Assessment Scale) scale, to assess disability attributed to migraine. |
| Secondary | PGIC | Through study completion, an average of 2 years. | PGIC (Patien Global Impression of Change) scale will be used to assess impression of change in migraine patients. |
| Secondary | BAI | Through study completion, an average of 2 years. | Change in BAI (Beck Anxiety Inventory) scale, to assess anxiety in migraine patients. |
| Secondary | BDI-II | Through study completion, an average of 2 years. | Change in BDI-II (Beck's Depression Inventory, 2nd version) scale, to assess depression in migraine patients. |
| Secondary | MSQ Version 2.1 | Through study completion, an average of 2 years. | Changes in MSQ (Migraine-Specific Quality-of-Life) Version 2.1 scale, to assess patient's quality of life. |
| Secondary | WPAI | Through study completion, an average of 2 years. | Changes in WPAI (Work Productivity and Activity Impairment) questionnaire, to assess how migraine impacts in work and productivity in migraine patients. |
| Secondary | ISI | Through study completion, an average of 2 years. | Changes in ISI (Insomnia Severity Index) scale to assess insomnia in migraine patients. |
| Secondary | ASC-12 | Through study completion, an average of 2 years. | Changes in ASC-12 (Allodynia Symptom Checklist) scale, to assess allodynia in migraine patients. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07159750
GET https://conductscience.org/api/trials/v1/NCT07159750/registered